The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin

The Effect On Transthyretin Stabilization, Safety, Tolerablity, Efficacy And Pharmacokinetics Of Orally Administered Tafamidis In Transthyretin Amyloid Polyneuropathy Patients With V30m Or Non-v30m Transthyretin: A Phase Iii, Open-label Study

Tafamidis has been developed as an oral specific stabilizer of transthyretin tetramer.

Inclusion Criteria:

• Transthyretin amyloid polyneuropathy with V30M or non-V30M transthyretin mutation.
• Subject had amyloid documented by biopsy in accordance with institutional site standard of care.

Exclusion Criteria:

• Primary amyloidosis and secondary amyloidosis.
• History of liver transplant.